Biotricity Inc. reported significant financial developments in its latest 10-Q filing for the six months ending September 30, 2025. The company generated revenue of $7.76 million, marking a 20% increase from $6.47 million in the same period last year. This growth was primarily driven by a 13.2% rise in technology fee revenue, which reached $6.88 million, while device sales contributed $877,000, accounting for 11.3% of total revenue. The gross profit for the period was $6.30 million, resulting in a gross margin of 81.2%, up from 74.6% in the prior year, attributed to improved margins on both technology fees and device sales.
In terms of operational efficiency, Biotricity reported a profit from operations of $555,764, a notable turnaround from a loss of $1.42 million in the previous year. Total operating expenses decreased to $5.74 million from $6.25 million, reflecting the company's focus on cost control. However, the net loss before dividends was $1.36 million, a significant reduction from $5.26 million in the prior year, indicating improved financial health. The company also reported a loss per share of $0.057, compared to $0.469 in the same period last year.
Biotricity's operational metrics showed positive trends, with the company expanding its sales efforts across 35 states and enhancing its product offerings, including the Bioflux and Biocore devices. The company has also made strides in customer retention, which has been crucial for its recurring revenue model. As of September 30, 2025, Biotricity had a working capital deficiency of $18.08 million, up from $15.99 million in March 2025, and an accumulated deficit of $140.97 million.
Looking ahead, Biotricity aims to continue its revenue growth trajectory while improving liquidity through business development and additional capital raises. The company is focused on the commercialization of its existing products and the development of new technologies, including advanced ECG algorithms and the next generation of its Biocore device. Management has expressed optimism about the potential for future profitability, contingent on achieving further regulatory approvals and maintaining a strong sales pipeline. However, the company acknowledges the need for additional funding to support its operations and growth initiatives, which may involve dilutive financing options.
About BIOTRICITY INC.
Biotricity Inc. develops FDA-cleared remote biometric monitoring solutions focused on cardiac diagnostics and chronic disease management. Its core products include the Bioflux and Biocore Pro ECG devices and the Bioheart continuous heart monitor, serving physicians, hospitals, and diagnostic testing facilities primarily in the U.S. The company’s insourced, technology-as-a-service model integrates hardware, software, and AI-driven analytics to enhance patient care, improve diagnostic accuracy, and enable cost-effective chronic cardiac care.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.